Study guide
15.1 Epidemiological Study Designs, Measures of Association & Bias
CAMC Regional Medical Registration Examination Part 1 MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, Registration Framework & Test Strategy
1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context
2 Chapter 2: Internal Medicine: Cardiovascular Disorders
2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension
3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care
3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax
4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders
4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis
5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology
5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies
6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases
6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship
7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies
7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications
8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care
8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management
9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care
9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies
10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications
10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia
11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology
11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)
12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition
12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies
13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies
13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health
14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology
14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects
15 Chapter 15: Community Health, Epidemiology & Preventive Medicine
15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control
16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology
16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses
17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements
17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation
15.1 Epidemiological Study Designs, Measures of Association & Bias
Key Takeaways Explain This Topic AI
Study design selection is governed by disease frequency, latency, and ethical boundaries: case-control studies are optimal for rare diseases, cohort studies for rare exposures, and randomized controlled trials (RCTs) for establishing causal therapeutic efficacy.
The Odds Ratio (OR = [a d] / [b c]) calculated in case-control studies mathematically approximates the true Relative Risk (RR) only under the rare disease assumption, when population prevalence is low (typically < 5% to 10%).
Intention-to-Treat (ITT) analysis evaluates all randomized participants in their initially assigned treatment arms regardless of non-compliance, protocol deviations, or dropout, preserving the randomized comparison. Missing outcome data can still cause attrition bias and need appropriate analysis.
Number Needed to Treat (NNT = 1 / ARR) reflects clinical therapeutic efficiency and must always be evaluated alongside the baseline risk and the exact timeframe over which the Absolute Risk Reduction is achieved.
Confounding requires an extraneous variable to be independently associated with both the exposure and outcome without lying on the causal pathway; it is controlled at the design phase (randomization, matching, restriction) or analysis phase (stratification, multivariable regression).
Last updated: November 2026
The Epidemiological Design Hierarchy
Epidemiological research provides the quantitative foundation for evidence-based medicine and public health policy across the Caribbean Community (CARICOM). In clinical practice and licensure examinations, candidates must critically evaluate research methodology, identify the appropriate design for a given research question, interpret measures of association, and detect systemic biases that threaten internal validity. Study designs are organized hierarchically according to their strength in establishing causal relationships, ranging from descriptive observations to secondary evidence syntheses.
Observational Descriptive Studies
Descriptive studies characterize health states by person, place and time. Case reports/series are descriptive; ecological and cross-sectional designs can also be analytic when they compare exposure–outcome associations :
Case Reports and Case Series : Detailed narrative descriptions of a single patient or a small aggregate of patients presenting with an unusual symptom complex, novel adverse drug reaction, or unexpected disease presentation (e.g., initial clinical descriptions of microcephaly associated with congenital Zika virus infection in the Caribbean basin). While invaluable for generating clinical hypotheses, case series lack a control group, preventing any determination of statistical association or disease causation.
Ecological (Correlational) Studies : Investigate associations between exposures and disease outcomes at the population or aggregate community level rather than the individual level (e.g., correlating per-capita refined sugar importation with national diabetes prevalence across fifteen CARICOM territories). The primary methodological vulnerability of ecological studies is the ecological fallacy —the erroneous inference that an association observed between aggregate population variables holds true for individual persons within that population.
Cross-Sectional Studies (Prevalence Surveys) :
Measure exposure status and disease outcome simultaneously in a defined population at a single, discrete point in time (a clinical 'snapshot').
Provide direct estimates of point or period prevalence (Prevalence = Total Existing Cases / Total Population at Risk), rendering them indispensable for public health resource planning and chronic disease burden monitoring (e.g., the Caribbean Health and Nutrition Surveys assessing adult hypertension prevalence).
Critical Limitation : Because exposure and outcome are assessed simultaneously, cross-sectional studies cannot establish temporal sequence (whether the exposure preceded the disease or vice versa), precluding causal inference.
Observational Analytic Studies
Analytic studies are explicitly designed to test directional hypotheses and quantify associations between exposures and outcomes:
Case-Control Studies (Outcome-to-Exposure Architecture) :
Retrospective by design: subjects are selected based on the presence ( cases ) or absence ( controls ) of the disease outcome. Investigators then look backward in time to determine the frequency of past exposure in both groups.
Clinical Indications : The optimal and most cost-effective design for studying rare diseases (e.g., toxic optic neuropathy or unusual pediatric sarcomas) or diseases with long latency periods, because assembling a sufficiently large cohort would be prohibitively slow and expensive.
Controls Selection : Controls must represent the source population that gave rise to the cases, with comparable opportunities for exposure. Select controls independently of the exposure being investigated .
Measure of Association : Because disease frequency is predetermined by the investigator (the case-to-control ratio, such as 1:1 or 1:4), true disease incidence cannot be calculated. The primary measure of association is the Odds Ratio (OR) :
Odds Ratio = Odds of exposure in cases Odds of exposure in controls = a / c b / d = a × d b × c \text{Odds Ratio} = \frac{\text{Odds of exposure in cases}}{\text{Odds of exposure in controls}} = \frac{a / c}{b / d} = \frac{a \times d}{b \times c} Odds Ratio = Odds of exposure in controls Odds of exposure in cases = b / d a / c = b × c a × d
The Rare Disease Assumption : The Odds Ratio mathematically approximates the true Relative Risk ( O R ≈ R R OR \approx RR OR ≈ RR ) only when the condition under study is rare in the general population (prevalence typically < 5 % < 5\% < 5% to 10 % 10\% 10% ).
Major Vulnerabilities : Highly susceptible to recall bias (patients with a severe disease dwell upon and report past exposures more thoroughly than healthy controls) and selection bias in control recruitment.
Cohort Studies (Exposure-to-Outcome Architecture) :
Subjects are selected strictly based on exposure status (exposed versus unexposed) and must be entirely free of the outcome of interest at baseline. The cohort is then followed over time to ascertain and compare the development of incident disease.
Prospective Cohort : Exposure is determined in the present, and the cohort is followed forward in chronological time.
Retrospective (Historical) Cohort : Exposure status was documented at a defined point in the past (e.g., occupational factory records from 1995), and the investigator reconstructs the timeline forward to the present using medical archives to determine disease incidence.
Clinical Indications : The optimal observational design for studying rare exposures (e.g., occupational exposure to sugarcane pesticide spraying or industrial bauxite dust) and evaluating multiple potential clinical outcomes resulting from a single exposure.
Measures of Association and Risk :
Incidence Proportion (Risk) : Over a specified follow-up, I e = a / [ a + b ] I_e = a / [a + b] I e = a / [ a + b ] in exposed and I u = c / [ c + d ] I_u = c / [c + d] I u = c / [ c + d ] in unexposed. In contrast, an incidence rate divides new cases by person-time at risk .
Relative Risk (Risk Ratio, RR) : Ratio of disease incidence in the exposed group compared to the unexposed group: Relative Risk (RR) = I e I u = a / ( a + b ) c / ( c + d ) \text{Relative Risk (RR)} = \frac{I_e}{I_u} = \frac{a / (a + b)}{c / (c + d)} Relative Risk (RR) = I u I e = c / ( c + d ) a / ( a + b ) Interpretation: R R = 1.0 RR = 1.0 RR = 1.0 indicates no association; R R > 1.0 RR > 1.0 RR > 1.0 indicates increased risk (harmful exposure); R R < 1.0 RR < 1.0 RR < 1.0 indicates protective effect.
Attributable Risk (Risk Difference, AR) : The excess disease incidence directly attributable to the exposure: Attributable Risk (AR) = I e − I u \text{Attributable Risk (AR)} = I_e - I_u Attributable Risk (AR) = I e − I u
Number Needed to Harm (NNH) : The number of individuals who must be exposed to the risk factor for one additional person to experience the adverse outcome: NNH = 1 Attributable Risk (AR) \text{NNH} = \frac{1}{\text{Attributable Risk (AR)}} NNH = Attributable Risk (AR) 1
Major Vulnerabilities : Costly, time-consuming, inefficient for rare diseases, and vulnerable to loss to follow-up (attrition bias).
Experimental Studies: Randomized Controlled Trials (RCTs)
Randomized Controlled Trials represent the gold standard for clinical evidence, providing the strongest proof of causality by directly manipulating the exposure (treatment intervention):
Randomization : Assigns participants to intervention or control arms strictly by chance, balancing known and unknown prognostic factors in expectation ; chance baseline imbalances can still occur in a particular trial.
Allocation Concealment : Prevents investigators and participants from knowing or influencing upcoming assignment sequences prior to enrollment, eliminating recruitment selection bias.
Blinding (Masking) :
Single-blind : Participants are unaware of their assignment.
Double-blind : Both participants and clinical trial investigators/caregivers are masked to treatment allocation, preventing performance and ascertainment biases.
Triple-blind : Commonly participants, clinicians and outcome assessors/data analysts are masked; specify who is blinded. An independent safety committee may review unblinded interim data under confidentiality safeguards.
Intention-to-Treat (ITT) Analysis :
Evaluates all randomized patients in the treatment group to which they were originally assigned , regardless of protocol violations, cross-overs, adverse drug reactions, or subsequent non-compliance.
Clinical Rationale : Preserves the randomized comparison and estimates the effect of treatment assignment. Missing outcomes can still cause attrition bias and require appropriate follow-up, analysis and sensitivity checks. A per-protocol analysis restricts participants by adherence; an as-treated analysis groups them by treatment actually received. Both can introduce confounding through post-randomization treatment decisions.
Measures of Clinical Efficacy :
Absolute Risk Reduction (ARR) : The absolute difference in event rates between control and experimental arms: ARR = I control − I treatment \text{ARR} = I_{\text{control}} - I_{\text{treatment}} ARR = I control − I treatment
Relative Risk Reduction (RRR) : The proportional reduction in event rate achieved by the intervention relative to baseline control risk: RRR = I control − I treatment I control = 1 − RR \text{RRR} = \frac{I_{\text{control}} - I_{\text{treatment}}}{I_{\text{control}}} = 1 - \text{RR} RRR = I control I control − I treatment = 1 − RR
Number Needed to Treat (NNT) : The number of patients who must receive the active therapeutic intervention over a specified timeframe to prevent one adverse clinical endpoint: NNT = 1 Absolute Risk Reduction (ARR) = 1 I control − I treatment \text{NNT} = \frac{1}{\text{Absolute Risk Reduction (ARR)}} = \frac{1}{I_{\text{control}} - I_{\text{treatment}}} NNT = Absolute Risk Reduction (ARR) 1 = I control − I treatment 1 Clinical Principle : NNT must always be integer rounded up to the next whole number (e.g., an NNT of 12.2 means 13 patients must be treated to prevent one event) and interpreted in conjunction with the baseline risk and follow-up duration.
Secondary Syntheses: Systematic Reviews and Meta-Analyses
Sitting atop the evidence pyramid, systematic reviews synthesize homogeneous primary studies using rigorous, pre-specified search protocols:
Forest Plot Interpretation : Each primary study is depicted as a horizontal line representing its 95% Confidence Interval (CI), with a square marking the point estimate (the size of the square represents the study's statistical weight/sample size). The vertical line of no effect represents R R = 1.0 RR = 1.0 RR = 1.0 (or mean difference = 0 = 0 = 0 ). A diamond at the bottom represents the pooled overall effect estimate; the lateral points of the diamond designate the 95% CI of the meta-analytic summary.
Statistical Heterogeneity ( I 2 I^2 I 2 Statistic) : Measures the percentage of variation across primary studies attributable to true heterogeneity rather than sampling error (chance):
I 2 < 25 % I^2 < 25\% I 2 < 25% : Low heterogeneity.
I 2 = 25 % − 50 % I^2 = 25\% - 50\% I 2 = 25% − 50% : Moderate heterogeneity.
I 2 > 50 % I^2 > 50\% I 2 > 50% : May indicate substantial heterogeneity. Assess clinical/methodological differences and uncertainty; do not choose random effects from this threshold alone . Model choice depends on the prespecified question and assumptions.
Publication Bias and the Funnel Plot : Plots study effect size against sample size (or standard error). In the absence of bias, studies scatter symmetrically in an inverted funnel shape around the true effect. Funnel plot asymmetry occurs when small studies with negative, non-significant findings remain unpublished in desk drawers (file-drawer problem), skewing the literature toward false positive benefits.
Systemic Biases and Confounding
Internal validity depends on minimizing systematic error (bias) and confounding, which cannot be corrected simply by expanding sample size.
Selection Bias
Systematic recruitment or retention differences can distort the exposure–outcome association. A nonrepresentative sample alone does not establish biased association estimates; it may instead limit generalizability:
Berkson's Bias (Admission Rate Bias) : When hospital admission depends on both exposure and disease, selecting hospitalized people can create or distort their association. Hospital controls are not automatically invalid ; their selection must represent the source population's exposure distribution rather than depend on the exposure being investigated.
Healthy Worker Effect : Observed in occupational epidemiology where working populations exhibit lower overall morbidity and mortality than the general population (which includes chronically ill, disabled, or retired persons), artificially diminishing occupational hazard risk estimates.
Attrition Bias : Differential loss to follow-up between study arms in a cohort study or RCT, compromising group comparability.
Information (Measurement) Bias
Occurs when data regarding exposure or outcome are systematically misclassified or incorrectly recorded:
Recall Bias : Differential recollection of past exposures between individuals with disease (cases) and healthy controls, classic in retrospective case-control designs.
Interviewer Bias : An investigator's knowledge of the subject's disease or exposure status unconsciously influences the thoroughness or wording of questioning.
Hawthorne Effect : Study subjects alter their baseline lifestyle, compliance, or health behaviors simply because they are aware of being actively observed.
Pygmalion (Rosenthal) Effect : Investigator enthusiasm or subconscious expectations influence treatment delivery or subjective assessment, eliminated by strict double-blinding.
Confounding and Methods of Control
A confounder is an extraneous variable that satisfies three strict epidemiological criteria:
It is independently associated with the exposure of interest.
It is an independent risk factor for the disease outcome.
It does not lie on the causal pathway between exposure and outcome (i.e., it is not an intermediate biological step).
Clinical Example : In assessing the association between heavy coffee drinking (exposure) and pancreatic carcinoma (outcome), cigarette smoking is a major confounder: coffee drinkers smoke more frequently than non-drinkers, and smoking is a direct causal agent for pancreatic cancer, but smoking is not an intermediate consequence of caffeine intake.
Methods to control confounding operate at two distinct phases:
At Study Design :
Randomization : Balances measured and unmeasured prognostic factors in expectation in experimental trials; it does not guarantee identical groups.
Restriction : Restricts study eligibility to individuals possessing specific characteristics (e.g., enrolling only non-smokers); eliminates confounding by the restricted variable but limits external generalizability.
Matching : Enrolls controls with identical confounding profiles (e.g., age, sex, smoking history) as cases.
At Data Analysis :
Stratification : Analyzing exposure-outcome associations separately within distinct strata of the confounding variable (e.g., calculating the OR between coffee and cancer separately among non-smokers and smokers). If stratum-specific ORs are identical to each other but differ from the crude overall OR, confounding is confirmed. (If stratum-specific ORs differ significantly from one another, effect modification [interaction] is present, which is a biological reality to be reported, not a bias to be eliminated).
Multivariable Regression Analysis : Mathematical modeling (logistic regression for binary outcomes, Cox proportional hazards for time-to-event outcomes) that isolates the independent effect of the primary exposure while statistically adjusting for multiple measured confounders simultaneously.
Comparative Summary of Study Designs
Study Design Temporal Sequence Direction of Inquiry Primary Measure of Association Primary Strengths Primary Vulnerabilities
Ecological Snapshot Aggregate population Correlation coefficient ( r r r ) Rapid; generates hypotheses; utilizes public records Ecological fallacy; cannot infer individual risk
Cross-Sectional Simultaneous Single point in time Prevalence Ratio / Odds Ratio Estimates disease burden; cost-effective Lacks temporality; cannot calculate incidence
Case-Control Retrospective Outcome to Exposure Odds Ratio (OR) Optimal for rare diseases and long latency Severe recall bias; Berkson's bias; no direct incidence
Cohort Prospective or Retrospective Exposure to Outcome Relative Risk (RR) & Attributable Risk (AR) Directly establishes incidence and temporality; optimal for rare exposures High cost; loss to follow-up (attrition); inefficient for rare diseases
Randomized Controlled Trial Prospective Exposure (Intervention) to Outcome Relative Risk (RR), ARR, RRR, NNT Gold standard for causal treatment comparison; reduces confounding through random allocation Ethical restrictions; expensive; strict criteria limit generalizability
Meta-Analysis Synthesis Aggregated published trials Pooled RR / OR / Mean Difference Maximizes statistical power; resolves conflicting literature Publication bias; garbage-in/garbage-out if primary trials are flawed